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Abstract
Introduction: This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast
and to examine interactions between apremilast, methotrexate and adenosine A2A receptors (A2AR).
Methods: After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10, IL-6 and IL-1α were measured in the
Raw264.7 monocytic murine cell line. PKA, Epac1/2 (signaling intermediates for cAMP) and A2AR knockdowns were
performed by shRNA transfection and interactions with A2AR and A2BR, as well as with methotrexate were tested
in vitro and in the murine air pouch model. Statistical differences were determined using one or two-way ANOVA or
Student’s t test. The alpha nominal level was set at 0.05 in all cases. A P value of < 0.05 was considered significant.
Results: In vitro, apremilast increased intracellular cAMP and inhibited TNF-α release (IC50=104nM) and the specific
A2AR-agonist CGS21680 (1μM) increased apremilast potency (IC50=25nM). In this cell line, apremilast increased IL-10
production. PKA, Epac1 and Epac2 knockdowns prevented TNF-α inhibition and IL-10 stimulation by apremilast. In the
murine air pouch model, both apremilast and MTX significantly inhibited leukocyte infiltration, while apremilast, but
not MTX, significantly inhibited TNF-α release. The addition of MTX (1 mg/kg) to apremilast (5 mg/kg) yielded no more
inhibition of leukocyte infiltration or TNF-α release than with apremilast alone.
Conclusions: The immunoregulatory effects of apremilast appear to be mediated by cAMP through the downstream
effectors PKA, Epac1, and Epac2. A2AR agonism potentiated TNF-α inhibition by apremilast, consistent with the
cAMP-elevating effects of that receptor. Because the A2AR is also involved in the anti-inflammatory effects of MTX,
the mechanism of action of both drugs involves cAMP-dependent pathways and is therefore partially overlapping
in nature.
Introduction
Accumulating data since the 1950s describe the pro-
perties of cyclic adenosine monophosphate (cAMP) as a
pivotal second messenger in the regulation of inflamma-
tory responses [1]. Cyclic AMP-specific phosphodiester-
ases (PDE), therefore, have emerged as a new target for
the treatment of numerous inflammatory conditions
(reviewed in [2]) as the anti-inflammatory properties of
PDE inhibitors such as theophylline were being demon-
strated during the 1970s [3]. cAMP-specific phosphiodies-
terase type 4 (PDE4), a critical regulator of intracellular
cAMP levels and compartmentalization [4], is mainly
expressed within inflammatory cells [5]. Thus, inhibition
of PDE4 suppresses the expression of TNF-α, among
other cytokines and chemokines, by T cells and monocytes
[6–8]. PDE4 inhibitors are well-characterized pharma-
ceutical agents with a broad range of anti-inflammatory
activity, as documented by numerous studies of low
molecular-weight PDE4 inhibitors, such as rolipram [9].
The clinical development of a class of PDE4 inhibitor
anti-inflammatory agents has been hindered by their side
effects, principally nausea and emesis [10]. Indeed, des-
pite their potential as anti-inflammatory agents, PDE4
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inhibitors have failed clinical trials due to the high
prevalence of these and other side effects [11] such as
headache, diarrhea, fatigue, dyspepsia, nasopharyngitis
and gastroenteritis [12]. Thus, a major pharmaceutical
research focus in the field of chronic inflammatory dis-
eases was the development of novel PDE4 inhibitors
with high therapeutic index [13]. The novel PDE4 inhibi-
tor, apremilast, has a higher therapeutic index and was
developed, introduced to the clinic [14, 15] and recently
approved in the USA for the treatment of psoriatic
arthritis (reviewed in [2]).
Unlike TNF-α inhibitors, which bind directly to TNF-α,
PDE4 inhibitors inhibit TNF-α production at the level of
gene expression and do not completely suppress TNF-α
levels in clinical settings. Rather, apremilast causes a
broad, but not complete, inhibition of multiple pro-
inflammatory mediators [16]. It is well-known that PDE4
inhibition promotes intracellular accumulation of cAMP,
activation of Protein kinase A (PKA) and phosphorylation
of the cAMP-response element binding protein (CREB),
which, in turn, suppresses the transcription of numerous
cytokines, such as TNF-α, exerting therefore an overall
anti-inflammatory effect [9]. However, the specific impact
of apremilast on the expression of different cytokines and
the role of other downstream effectors of cAMP, i.e.,
Exchange protein directly activated by cAMP (Epac)1 and
Epac2, in the mechanism of action of apremilast have not
been previously addressed, nor has the interaction of
apremilast with other systems that regulate cAMP levels,
such as adenosine receptors, in particular with the A2A
adenosine receptor (A2AR), which mediates many of the
anti-inflammatory actions of methotrexate (MTX), the
cornerstone treatment for rheumatoid arthritis [17].
Therefore, the aim of the present work was to analyze the
downstream pathways triggered by apremilast and to test
potential interactions of apremilast with MTX, and with
the adenosine receptors in both in vitro and in vivo
models of inflammation.
Materials and methods
Air pouch model
As previously described [17], male mice were given weekly
intraperitoneal injections of either MTX (1mg/Kg) or
vehicle (phosphate-buffered saline; PBS) for 4 weeks. Air
pouches were generated by subcutaneous injection of
3 ml of sterile air and reinflated with 1.5 ml of sterile
air 2 days later. Vehicle (0.5 % carboxymethylcellulose
and 0.25 % Tween 80) or apremilast (5 mg/Kg) were or-
ally dosed, with a syringe through a blunt-ended curved
feeding tube, 24 h and 1 h before inflammation was in-
duced on day 6 by injection of 1 ml of 2 % carrageenan
suspension. Four hours later, mice were killed by CO2
narcosis, and exudates harvested with 2 ml PBS. Leuko-
cytes were counted in a hemocytometer chamber and
concentrations of cytokines were measured by ELISA
or by the Luminex platform as described below. All
protocols followed internationally recognized guidelines
and were approved by the New York University School of
Medicine Institutional Animal Care and Use Committee
(NYU SoM, IACUC, protocol number 130412).
Histology
Four-micron formalin-fixed, paraffin-embedded tissue
sections were stained with H&E or with toluidine blue
histochemicals by incubating sections in aqueous 0.01 %
toluidine blue for 5 minutes. Slides were washed in dis-
tilled water, quickly dehydrated through graded alcohols,
cleared in xylene and mounted with synthetic permanent
media [18].
Immunohistochemistry was performed on four-micron
formalin-fixed, paraffin-embedded mouse skin tissue
sections using rabbit anti-mouse CD3 (Ventana Medical
Systems Tucson, AZ, USA) clone 2GV6, rat anti-mouse
CD45R (BD Biosciences San Diego, CA, USA) clone
RA3-6B2, rat anti-mouse CD68 (Abd Serotech, Raleigh,
NC, USA) clone FA-11 and rat anti-mouse neutrophil
(Abcam Cambridge, MA, USA) clone NIMP-R14. In brief,
sections were deparaffinized in xylene (three changes),
rehydrated through graded alcohols (three changes 100 %
ethanol, three changes 95 % ethanol) and rinsed in distilled
water. For CD3, heat-induced epitope retrieval was per-
formed in a 1200-Watt microwave oven at 100 % power in
10 mM sodium citrate buffer, pH 6.0 for 20 minutes. Sec-
tions were allowed to cool for 30 minutes and then rinsed
in distilled water. Antibody incubations and detection were
carried out at 37 °C on a Discovery or NEXes instrument
(Ventana Medical Systems Tucson, AZ, USA) platform
using Ventana reagent buffer and detection kits unless
otherwise noted. Endogenous peroxidase activity was
blocked with hydrogen peroxide. Tissue sections for CD68
and anti-neutrophil were digested at 37 °C with alkaline
endopeptidase for 12 and 6 minutes, respectively. All
antibodies were diluted in Dulbecco’s Phosphate-Buffered
Saline (Life Technologies Grand Island, NY, USA). CD3
and CD45R were diluted 1:10 and incubated for 30 mi-
nutes. CD68 was diluted 1:10 and anti-neutrophil 1:1600
and incubated for 12 h at room temperature. CD3 was de-
tected with biotinylated goat anti-rabbit (Vector Labora-
tories Burlingame, CA USA) diluted 1:200. CD45R and
anti-neutrophil were detected with biotinylated goat anti-
rat diluted 1:200 and CD68 was detected using biotinyl-
ated rabbit anti-rat, mouse absorbed (Vector Laboratories
Burlingame, CA, USA) diluted 1:100. Secondary antibodies
were incubated for 30 minutes at 37 °C. This was followed
by the application of streptavidin-horseradish-peroxidase
conjugate. The complex was visualized with 3,3 diamino-
benzidene and enhanced with copper sulfate. Slides were
washed in distilled water, counterstained with hematoxylin,
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dehydrated through graded alcohols, cleared in xylene and
mounted with synthetic permanent media. Appropriate
positive and negative controls were included with the
study sections.
cAMP measurements
Intracellular cAMP was measured with the direct cAMP
ELISA kit from Enzo Life sciences (Plymouth Meeting,
PA, USA). Fifty-percent-confluent Raw 264.7 cells were
starved for 24 h and stimulated at the indicated concen-
trations of apremilast for 30 minutes, and then with
lipopolysaccharide (LPS) for 20 minutes, and cAMP was
analyzed according to the manufacturer’s protocol.
TNF-α measurement
Raw 264.7 cells (100,000) were grown in 96-well plates.
After 24 h, cells were stimulated with vehicle (final concen-
tration of 0.025 % dimethyl sulfoxide (DMSO)) or with
apremilast at the indicated concentrations. After 30 minutes
cells were stimulated with LPS (L5886; Sigma, St Louis,
MO, USA) 1 μg/ml for 4 h. When studying CGS21680
(1063; Tocris Bioscience, Ellisville, MO, USA), SCH58261
(2270; Tocris Bioscience), ZM241385 (1036; Tocris
Bioscience), BAY60-6583 (4472; Tocris Bioscience), or
GS6201 (4727; Tocris Bioscience), the adenosine recep-
tor ligands were added 15 minutes before apremilast.
Methotrexate (Hospira Inc, Lake Forest, IL, USA) was
added 24 h and 1 h before apremilast. Supernates were
then collected and TNF-α levels were quantified with
the Mouse TNF-α Quantikine ELISA Kit (MTA00B;
R&D systems; Minneapolis, MN, USA) following the
manufacturer’s instructions.
IC50 calculation and statistics
IC50 (EC50) calculations were made using non-linear re-
gression, sigmoidal dose–response, constraining the top
to 100 % and bottom to 0 %, allowing variable slope,
using GraphPad Prism v6.00.
Western blotting
Seventy-percent-confluent Raw 264.7 cells were starved
for 24 h and stimulated with apremilast for 30 minutes
and then with LPS for different time points (n = 4),
Cells were lysed with radioimmunoprecipitation assay
(RIPA) buffer and protein concentration was deter-
mined by bicinchoninic acid (BCA). Protein (4 μg) was
subjected to 7.5 or 10.0 % SDS-PAGE and transferred
to a nitrocellulose membrane. Nonspecific binding was
blocked with TBS/Tween-20 0.05−3 % BSA. Mem-
branes where incubated overnight (4 °C) with primary
rabbit polyclonal anti-pCREB (Abcam, Cambridge, MA,
USA), mouse monoclonal anti-CREB (Abcam), rabbit
polyclonal anti-PDE4 (Abcam) and mouse monoclonal
anti-Actin (1:1000 each). Membranes were incubated
with goat anti-rabbit IRDye 800CW 1:10000 and goat
anti-mouse IRDye 680 RD 1:10000 (Li-cor Biosciences) in
the dark. Proteins were visualized by Li-cor Odyssey
equipment, which detects near-infrared fluorescence. As
each secondary antibody emits a signal in a different
spectrum, reprobing with actin (to check that all lanes
were loaded with the same amount of protein) was per-
formed simultaneously with primary antibody incubation.
Intensities of the respective band were quantitated by
densitometric analysis using Image Studio 2.0.38 software
(Li-cor Biosciences). Variations in band intensity were
expressed as the percent of unstimulated controls, to
minimize disparities among different experiments.
Quantitative reverse transcription (RT)-PCR
Total RNA was extracted and purified using the RNeasy
Mini Kit (QIAGEN, Valencia, CA, USA) according to
the manufacturer’s protocol. Relative quantification of
gene expression was performed using real-time RT-PCR
on the Mx3005P Real-Time PCR System (Strategene,
Agilent technologies Santa Clara, CA, USA) with SYBR
Green (Agilent technologies, 600548, Santa Clara, CA,
USA) according to the manufacturer’s protocol. The fol-
lowing primers were used in real-time PCR amplification:
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
forward: 5 -CTACACTGAGGACCAGGTTGTCT −3, re-
verse: 5- GGTCTGGGATGGAAATTGTG −3; Protein
kinase A (PKA) forward: 5- CAGGAAAGCGCTCCAGA
TAC −3, reverse: 5- AAGGGAAGGTTGGCGTTACT −3;
Epac1 forward: 5- GTTGTCGACCCACAGGAAGT −3,
reverse: 5- ACCCAGTACTGCAGCTCGTT −3; Epac2
forward: 5- GCATTGAGCAGGAGGACTTC −3, reverse:
5- AACGTGGGGTTCAATGAGAG −3; A2AR forward:
5- AGCCAGGGGTTACATCTGTG −3, reverse: 5- TAC
AGACAGCCTCGACATGTG −3. mRNA abundance was
determined relative to that of GAPDH.
Luminex assay
Quantification of cytokines and chemokines was per-
formed using Luminex x-MAP technology (Luminex Corp,
Austen TX, USA). Tissue culture supernatants and mouse
exudates were analyzed for expression of IL-1α, IL-6 and
IL-10 using a Milliplex multi-analyte magnetic bead panel
from EMD Millipore (MCYTOMAG-70K, Billerica, MA,
USA). Assays were performed according to the kit proto-
col using the appropriate matrix solution (culture media
or PBS for supernatants and exudates, respectively). Data
were collected on a Luminex 200 instrument and analyzed
using Analyst 5.1 software (Millipore) with four-parameter
logistic curve fitting. Samples were assayed in duplicate.
All standard curves generated from the known reference
cytokine concentrations supplied by the manufacturer had
R2 values calculated at or close to 1 and percent recovery
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between 80 and 120 %. Quality controls included with
each kit performed as expected.
Transfection protocol
We have previously reported on the stably transduced PKA,
Epac 1 and Epac 2 knockdown Raw 264.7 cells and shown
that there was a marked reduction in the expression of
these proteins [19]. Briefly, Raw 264.7 cells (15,000 cells/ml)
were plated and 24 h later cells were incubated, in the pres-
ence of hexadimethrine bromide (4 μg/ml), with 108 lenti-
viral transduction particles corresponding to mouse PKA
catalytic alpha subunit shRNA (SHCLNV-NM_008854)
EPAC1 (RAPGEF3, SHCLNV-NM_144850) or EPAC2
(RAPGEF4, SHCLNV-NM_019688) with puromycin se-
lection marker for another 24 h, to allow transfection.
Media was then replaced with αMEM containing puro-
mycin (1 ug/ml), changing the media every 3 days until se-
lected clones formed. These clones were isolated and
expanded until confluence. Scrambled shRNA (SHC002V)
was used as control. Permanently silenced clones were
kept in culture under puromycin selection.
Statistical analysis
Statistical differences were determined using one-way or
two-way analysis of variance (ANOVA) or Student’s t test
carried out using GraphPad software (v 6.00, GraphPad
Software, Inc.) on a PC. The alpha nominal level was set
at 0.05 in all cases. A P value <0.05 was considered
significant.
Results
Apremilast and methotrexate independently prevent
inflammation in vitro and in the murine air pouch in vivo
model of inflammation
Apremilast has previously been shown to inhibit TNF-α
production from human rheumatoid synovial cells and
this ameliorates arthritis in the experimental model of
collagen-induced arthritis [20]. Interestingly, in the air
pouch model, an in vivo model that mimics the synovial
cavity, we have also demonstrated that the anti-
inflammatory actions of MTX, the cornerstone treat-
ment for rheumatoid arthritis, are mediated in large
part, by increasing adenosine levels [17], which, via acti-
vation of the A2AR, increase intracellular cAMP levels
[21]. We therefore sought to study apremilast and MTX
combined anti-inflammatory actions in both in vivo and
in vitro models.
In vivo, an air pouch was formed on the dorsum of the
mice (Fig. 1a), and the characteristic air pouch membrane
was formed (A.M.; H&E on Fig. 1b) [22] with a cell infiltrate
comprised almost exclusively of neutrophils. Among cells
forming the cellular infiltrate, we also found a small quantity
of CD3+ T cells, but we did not detect any B cells, macro-
phages or mast cells, as analyzed by immunohistochemistry
with B220 and CD68 markers, and by toludine blue stain,
respectively.
Apremilast, orally administered (5 mg/Kg), signifi-
cantly inhibited TNF-α production in the air pouch by
39 % (61 ± 6 % of vehicle, P <0.001) and diminished (by
28 %) the number of leukocytes present (72 ± 12 % of
vehicle, P <0.05; Fig. 2a). In agreement, immunohistolo-
gic analysis shows that neutrophil accumulation in the
air pouch membrane was dramatically reduced by apre-
milast (Fig. 2b). We measured different mediators of in-
flammation with the Luminex multiplex platform and
found that apremilast treatment did not significantly
change the levels of IL-1α, IL-10 and IL-6 in the air
pouch exudates (Fig. 2c).
We next pretreated mice with low-dose MTX (1mg/Kg,
one dose per week for 4 weeks) prior to apremilast treat-
ment, and studied the inflammation of the air pouch. As
shown in Fig. 2d, both apremilast and MTX decreased
leukocyte accumulation, and apremilast significantly re-
duced TNF-α levels. When administered together there
was no additive reduction of either TNF-α or leukocyte
accumulation in the air pouch. Similarly, no differences
were found for the levels of IL-1α, IL-6 and IL-10
treated with apremilast + MTX or apremilast alone
(not shown). Because many, but not all of the actions
of MTX, working through A2AR, were identical and not
additive, our results and prior published data suggest
that the actions of these agents in suppressing in-
flammation might be mediated by similar signaling
pathways. Thus, we analyzed the intracellular pathways
activated by apremilast in vitro.
Apremilast increases intracellular cAMP and inhibits
TNF-α release by LPS in the mouse macrophage Raw
264.7 cell line
Apremilast inhibits PDE4 with an IC50 of 74 nM using
1 μM cAMP as substrate [16]. Although apremilast is not
selective for the different PDE4 isoforms (PDE4A4,
PDE4B2, PDE4C2 and PDE4D3), as studied with recom-
binant enzymes, it is indeed PDE4-selective as it did not
show significant inhibition of other PDE families at 10 μM
[16]. As shown in Fig. 3a, the Raw 264.7 cell line ex-
pressed several different isoforms of PDE4 and apremilast
significantly increased intracellular cAMP, whether or not
cells were challenged by LPS (Fig. 3b, two-way ANOVA
analysis; apremilast vs control, P <0.001; apremilast plus
LPS vs vehicle, not significant), which suggests that the
apremilast-mediated cAMP increase is independent of
macrophage activation. Consistent with the functional
effects of the apremilast-induced increase in cAMP
concentrations, apremilast promoted phosphorylation
of CREB (Fig. 3c), in agreement with the hypothesis
that apremilast activates the anti-inflammatory cAMP/
p-CREB pathway [23].
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As expected, LPS increased TNF-α release (from
1,345 ± 273 pg/ml to 9,624 ± 1,755 pg/ml; P <0.01). A
dose−inhibition curve was performed to analyze the
impact of increasing concentrations of apremilast
showing that apremilast inhibited TNF-α release by
LPS with an IC50 of 104 nM (pIC50 = 6.98 ± 0.2;
Fig. 3d), which almost exactly replicates previous reported
TNF-α inhibition by apremilast on peripheral blood
mononuclear cells (PBMCs) (IC50 = 110 nM) and which is
similar to the potency of apremilast for PDE4 enzymatic
inhibition (IC50 = 74 nM) [24]. These results are clearly
consistent with the hypothesis that apremilast inhibits
TNF-α by increasing intracellular cAMP levels.
A2AR, but not A2BR, activation and apremilast exert
additive TNF-α inhibition
Adenosine, a purine nucleoside generated by the dephos-
phorylation of adenine nucleotides, exerts potent anti-
inflammatory actions [21]. Indeed, adenosine inhibits
TNF-α, IL-6 and IL-12 release and augments IL-10
production stimulated by LPS mostly through activation
of the A2AR, a G protein coupled receptor [25–27].
Moreover, there is evidence that the A2BR exerts anti-
inflammatory actions as well, as it was found that A2BR
augments LPS-induced IL-10 production in the Raw 264.7
cell line [28]. As both the A2AR and the A2BR couple to
Gs protein and increase intracellular cAMP production
Fig. 1 Air pouch model of inflammation. a Inflammation in the air pouch was induced as described. b H&E reveals the formation of the air pouch
membrane (A.M.) and immunohistology staining with specific neutrophil (Neut), T cell (CD3), B cell (B220) and macrophage (CD68) markers, and the
toluidine blue stain for mast cells was performed
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[21] we hypothesized that apremilast may enhance the ac-
tions of both A2AR and A2BR. When the specific A2AR
agonist CGS21680 (1 μM) was added to apremilast there
was a significant reduction in the IC50 for apremilast inhib-
ition of TNF-α release, from 104 nM to 25 nM (pIC50 of
apremilast + vehicle vs pIC50 of apremilast + CGS21680
1 μM: P <0.0001, Student’s t test; Fig. 4a), indicating that
A2AR activation and apremilast were additive. However,
co-stimulation with CGS21680 and apremilast did not fur-
ther increase intracellular cAMP levels when compared to
either agent alone, though there was some additivity noted
at the lower concentrations of CGS21680 and apremilast
(Additional file 1: Figure S1). Interestingly, when the im-
pact of two different A2AR antagonists (SCH58261 1 μM
and ZM241385 1 μM) on the TNF-α inhibition by apremi-
last was studied, no significant changes were found
Fig. 2 Apremilast and methotrexate (MTX) prevent inflammation in the air pouch independently. Mice were orally treated with apremilast (5 mg/Kg),
and inflammation in the air pouch was induced as described under “Materials and methods”. a TNF-α and leukocyte accumulation were quantified in
the exudates of the air pouch. b Immunohistology reveals a decrease in the number of neutrophils (Neut) by apremilast treatment. c IL-1α, IL-6 and
IL-10 levels were measured in the air pouch exudates with the Luminex multiplex technology. d TNF-α and leukocyte were quantified in the air pouch
exudates in mice after weekly intraperitoneal injections of MTX (1 mg/Kg) for 4 weeks prior to apremilast treatment. Data represent mean ± standard
error of the mean of at least three independent experiments. Statistical analysis was performed by the Student’s t test or one-way ANOVA, where
***P <0.001, **P <0.01 and *P <0.05 vs vehicle
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(Fig. 4b), indicating that A2AR blockade alone does not
prevent apremilast inhibition of TNF-α despite the inter-
action between A2AR activation and PDE4 inhibition.
Further corroboration that diminished A2AR activity does
not interfere with apremilast, is provided by the finding that
when the A2AR was knocked down (A2AR shRNA: 54 %
Fig. 3 Apremilast inhibits lipopolysaccharide (LPS)-induced TNF-α release via cyclic adenosine monophosphalphate (cAMP). a Western blot of
PDE4 was performed in the Raw 264.7 cell line. b Raw 264.7 cells were incubated with increasing concentrations of apremilast 30 minutes before
incubation with or without LPS 1 μM during 20 minutes. Intracellular cAMP levels were then measured as described under “Materials and methods”.
c Western blot of p-cAMP responsive element binding protein (p-CREB) and CREB shows that apremilast promotes CREB phosphorylation after incubation
with LPS 1 μg/ml for 30 minutes. d Cumulative concentration response curves to apremilast (6 nM−1 μM) were performed in the Raw 264.7
cells 30 minutes before incubation with LPS 1 μM during 4 h. IC50 values were determined as described under “Materials and methods”. Data represent
means ± standard error of the mean of four independent experiments. Statistical analysis was performed by two-way ANOVA: apremilast ***P <0.001,
LPS: not significant. PDE4 phosphodiesterase 4,
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expression compared to non-target shRNA) apremilast
inhibited TNF-α production by LPS to a similar extent
(non-target shRNA: 81 ± 2 % TNF-α inhibition vs A2AR
shRNA: 66 ± 9 %, P <0.05).
Next, we studied the impact of a specific A2BR agonist
(BAY60-6583 1 μM) and a specific A2BR antagonist (GS
6201 1 μM) on apremilast-mediated inhibition of TNF-α
release. Neither the specific A2BR agonist nor the antag-
onist significantly affected apremilast-mediated inhib-
ition of TNF-α release (Fig. 4c, c), indicating that the
A2BR does not modulate the anti-inflammatory effects of
apremilast.
Previous work has shown that MTX exerts its anti-
inflammatory actions by increasing adenosine activation
of the A2AR [25–27], so we analyzed the impact of MTX
on TNF-α release by LPS. As expected from previous re-
ports studying the anti-inflammatory mechanism of
MTX in vitro [29], MTX inhibited the TNF-α increase
upon LPS challenge by as much as 77 ± 15 % (MTX
25 nM; n = 3) in the Raw 264.7 cell line (Fig. 5). However,
the combination of MTX + apremilast at a wide range of
concentrations of both agents (apremilast 0.1, 50.0 and
1000.0 nM; MTX 0.12, 0.25, 0.5, 1.0 and 10.0 μM) did not
differ from apremilast alone with respect to inhibition of
TNF-α (not shown), suggesting that the mechanisms of
both MTX and apremilast regulation of TNF-alpha are
overlapping.
Role of PKA and Epac1/2 in the anti-inflammatory actions
of apremilast
In eukaryotic cells, the effects of cAMP are mainly medi-
ated by two ubiquitously expressed intracellular cAMP-
regulated signaling proteins, PKA and the Exchange protein
directly activated by cAMP/cAMP-regulated guanine nu-
cleotide exchange factors (Epac1/2) [30], and by the cyclic
nucleotide-gated ion channels [31]. We next examined the
Fig. 4 Combined effects adenosine A2A receptor (A2AR), adenosine ABA receptor (A2BR) and apremilast on inhibition of TNF-α release. Cumulative
concentration response curves to apremilast (6 nM−1 μM) were performed in the Raw 264.7 cells 30 minutes before incubation with lipolysaccharide
(LPS) 1 μM during 4 h. We added CGS21680 1 μM (a), SCH 58261 1 μM or ZM 241385 1 μM (b), BAY60-6583 1 μM (c) or GS 6201 1 μM (d) 15 minutes
before apremilast. IC50 values were determined as described under “Materials and methods”. Data represent means ± standard error of the mean of
three to four independent experiments
Fig. 5 Methotrexate (MTX) inhibits TNF-α release upon lipopolysaccharide
(LPS) challenge. Raw 264.7 cells were incubated with increasing
concentrations of MTX 24.0 h and 1.5 h before incubation without
LPS 1 μM during 4 h. TNF-α levels were then measured as described
under “Materials and methods”. Data represent means ± standard error
of the mean of four independent experiments
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role of PKA and Epac1/2 in the anti-inflammatory effects
mediated by PDE4 inhibition by apremilast.
We have previously shown that knocking down Epac1,
Epac2 or PKA in the RAW264.7 cell line by cellular
transduction with lentiviruses that express selective
shRNA yields more selective information about the roles
of Epac1, Epac2 or PKA in regulating cellular functions
than their respective pharmacological inhibitors BFA
[19] or the PKA inhibitor TTYADFIASGRTGRRNAIHD
[32]. We confirmed that these previously permanently
transduced cells expressed less messaging for the target
proteins and observed a specific decrease of 61 %, 77 %
and 60 %, respectively, for the PKA, Epac1 and Epac2
knockdown cells (Fig. 6a). In agreement, in the Raw
264.7 cell line, protein levels were dramatically decreased
with the specific shRNAs (previously reported in [19] and
in Additional file 2: Figure S2). In non-target shRNA-
transfected cells, LPS increased TNF-α from 442.6 ± 57.2
Fig. 6 Effect of Protein kinase A (PKA), Exchange protein directly activated by cAMP (Epac)1 and Epac2 knockdown on the action of apremilast.
a Transfection of Raw 264.7 cells with shRNA for PKA, Epac1 or Epac2 reduce PKA, Epac1 and Epac2 expression, respectively, as shown by RT-PCR.
b PKA, Epac1 and Epac2 knockdown Raw 264.7 cells were incubated with apremilast 100nM for 30 minutes before incubation with or without
lipopolysaccharide (LPS) 1 μM during 4 h. Levels of TNF-α, IL-10, IL-6 and IL-1α were analyzed by ELISA or with the Luminex multiplex technology
as described under “Materials and methods”. Data represent means ± standard error of the mean of three independent experiments. Statistical
analysis was performed by one-way ANOVA with the Bonferroni posttest correction; ***P <0.001, **P <0.01 vs non-target
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to 9731.6 ± 2500.4 pg/ml (P <0.05) and apremilast treat-
ment (100 nM) inhibited TNF-α production by 76 ± 3 %
(Fig. 6b), whereas knockdown of PKA, Epac1 and Epac2 re-
duced apremilast-mediated inhibition to 44 ± 4%, 48 ± 5 %
and 51 ± 7 % inhibition, respectively. These results suggest
that cAMP-mediated inhibition of TNF-α production is
mediated via PKA and Epac1/2 activation.
To further study the anti-inflammatory effects of apre-
milast we analyzed the effect of apremilast on cytokine re-
lease with the Luminex multiplex platform. Among
cytokines increased by LPS (IL-10, IL-6 and IL-1α), in
non-target shRNA transfected cells apremilast further in-
creased IL-10 (from 32 ± 7 to 181 ± 33 pg/ml, P <0.05).
Apremilast showed a trend to increase IL-6 in this murine
cell line (from 811 ± 416 to 1,986 ± 881 pg/ml, P <0.05)
and modestly diminished the LPS-mediated increase of
IL-1α (from 149 ± 26 to 97 ± 35 pg/ml, P <0.05). Interest-
ingly, all three knockdowns for PKA, Epac1 and Epac2,
prevented the apremilast-mediated increase of IL-10, but
knockdown of these signaling molecules did not affect
apremilast-mediated regulation of IL-6 and IL-1α levels
(Fig. 6b, lower panels).
Discussion
PDE4 is the predominant cAMP-selective phosphodiester-
ase regulating the function of inflammatory cells [5] and
selective PDE4 inhibitors have therefore generated great
interest for the treatment of immune diseases, including
inflammatory arthritis. Unfortunately most PDE4 inhibi-
tors, such as rolipram, induce a variety of side effects, in-
cluding nausea and emesis, because PDE4 is also highly
expressed in the central nervous system [10]. As a conse-
quence, early clinical studies with PDE4 inhibitors failed
to demonstrate benefit due to the high incidence of these
adverse effects [11].
Apremilast was discovered through evaluation of
substitutions on a chemical scaffold, to optimize the
structure-activity relationship of a particular series of
PDE4 inhibitors [14, 15]. The orally available PDE4
inhibitor inhibits spontaneous TNF-α production from
human synovial membrane cultures and reduces the se-
verity of disease in murine models of arthritis with simi-
lar efficacy to rolipram, but without any significant
adverse effects [20]. Moreover, apremilast has been well-
tolerated in clinical trials, with a favorable benefit to risk
profile [33, 34] and has recently been approved for the
therapy of psoriatic arthritis.
In the air pouch model of inflammation in vivo, which
mimics the synovial cavity in rheumatoid arthritis, we
found an inflammatory exudate composed primarily of
neutrophils with a small number of T cells (Fig. 1).
Apremilast dramatically decreased the accumulation of
neutrophils and inhibited TNF-α and IL-1α production,
while at the same time increasing the levels of the anti-
inflammatory cytokine IL-10 (Fig. 2), further corroborating
the pleiotropic anti-inflammatory actions of apremilast.
Apremilast is a well-described inhibitor of PDE4 [14],
as measured on PDE4 and recombinant PDE4 isolated
from cells [14, 16, 35]. The present work shows that
apremilast increases intracellular cAMP in cell systems,
consistent with PDE4 inhibition and previous data [15].
We found that apremilast promoted a significant in-
crease of cytosolic cAMP in the Raw 264.7 cell line inde-
pendently of LPS stimulation (Fig. 3b). Moreover, the
potency of TNF-α inhibition by apremilast in these cells
(IC50 104 nM) was nearly identical to that for its re-
ported inhibition of PDE4 activity (IC50 74nM) and
TNF-α inhibition in peripheral blood mononuclear cells
(IC50 = 110 nM, [16]). As expected, these findings indicate
that PDE4 inhibition by apremilast suppresses TNF-α pro-
duction by increasing cAMP.
Interestingly, the anti-inflammatory action of MTX,
the cornerstone drug for the treatment of rheumatoid
arthritis and other inflammatory diseases [36], depends
on the extracellular conversion of adenine nucleotides to
adenosine [17]. Adenosine was described as an anti-
inflammatory agent nearly 30 years ago [21]. By binding
the A2AR, which signals almost exclusively by increasing
intracellular cAMP levels [37], adenosine has been shown
to inhibit TNF-α, IL-6 and IL-12 release, while it augments
IL-10 production induced by LPS [25–27]. We hypothe-
sized that apremilast and A2AR activation could interact at
the cAMP level. Therefore, we investigated the impact of
stimulation or blockade of the A2AR on the apremilast-
mediated inhibition of TNF-α production, finding that the
A2AR-specific agonist CGS21680 increases the potency of
apremilast from an IC50 of 104 nM to 25 nM (Fig. 4a).
However, in the presence of apremilast, CGS21680 did not
further increase the levels of cAMP (Additional file 1:
Figure S1) and A2AR pharmacological blockade (Fig. 4b)
did not further alter apremilast inhibition of TNF-α. This
apparent discrepancy might be explained by an insufficient
amount of endogenous adenosine production in the cellu-
lar system. Similarly, despite its potential link to enhanced
cAMP levels, A2BR activation or blockade did not affect
TNF-α inhibition by apremilast (Fig. 4c, d). Moreover, we
were surprised to find that apremilast showed a trend to
increase IL-6 production in vitro, although we did not
detect any increase in vivo. In contrast, stimulation of
A2AR diminishes IL-6 production [21]. Interestingly, treat-
ment with MTX diminishes circulating IL-6 levels in pa-
tients [38, 39] although the effect of the drug alone on IL-6
production in vitro is equivocal [40–42]. In patients with
psoriatic arthritis, apremilast has been shown to reduce
plasma levels of TNF- α, IL-6, and other pro-inflammatory
cytokines and chemokines [43].
The A2AR is the only Gs-coupled adenosine receptor
subtype that has not been reported to also couple to the
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Gq-protein [37] and thus, it signals almost exclusively by
increasing cAMP levels. The findings reported here sug-
gest that apremilast and A2AR activation most likely
interact by either transient cAMP signals and/or by
compartmentalized cAMP increases, as previously found
for prostaglandin E1 (PGE1), which triggers transient in-
creases in the cAMP concentration near the plasma
membrane, but not in total intracellular cAMP levels
[44]. Indeed, recent studies indicate that there are dis-
tinct cAMP-signaling microdomains controlled by spe-
cific PDEs, which can differentially regulate independent
processes controlled by cAMP [45–47], so this same sig-
naling molecule can have opposing effects within the
same cell due to a compartmentalized mechanism. On
the other hand, although MTX prevents TNF-α release
in vitro (Fig. 5) and inflammation in the air pouch via
adenosine release [17], we did not detect additive effects
of apremilast + MTX either in vitro (Fig. 5) or in vivo
(Fig. 2d), which is in agreement with the finding that no
additional benefit or risk is associated with combination
of apremilast and methotrexate therapy [48]. Indeed, in
a phase 3 study of apremilast demonstrating its efficacy
and safety in patients with psoriatic arthritis, the major-
ity of patients included in the trial were on concomitant
MTX therapy at baseline [49]. In order to rule out inter-
actions between apremilast and MTX, we tested a wide
range of concentrations of both agents in a variety of
combinations (apremilast 0.1, 50.0 and 1000.0 nM; MTX
0.12, 0.25, 0.5, 1.0 and 10.0 μM), finding a lack of inter-
action (data not shown), which may result from the vari-
ability of enhanced adenosine release in vitro leading to
greater variability in the inhibition due to MTX.
Targeting PDE4 has enormous clinical potential due to
its mechanism of action, which leads to increased intra-
cellular cAMP levels in many different inflammatory
cells, decreasing T cell and monocyte-derived cytokines
such as TNF-α [6–8]. From studies using the PDE4 in-
hibitors roflumilast and rolipram, it is known that PDE4
inhibition leads to decreased TNF-α gene expression by
a cAMP, PKA and NF-κB-dependent mechanism [9, 24].
Similarly, increased expression of the anti-inflammatory
cytokine IL-10 is enhanced by PDE4 inhibitors in a
PKA-dependent manner [50]. However, the discovery of
the exchange protein directly activated by cAMP (Epac)
suggested that the cAMP-mediated signaling mechanism
is much more complex [30], so that cAMP exerts its ef-
fects not only via PKA activation, but also via Epac [51].
In particular, it has been suggested that many anti-
inflammatory effects of cAMP are mediated via the PKA
pathway, while there are no major anti-inflammatory ac-
tions attributed to Epac [52, 53]. Moreover, prior studies
have yielded results that support the suggestion that
Epac activation following PDE4 inhibitor-mediated
cAMP increases has pro-inflammatory effects and that
addition of an Epac inhibitor to the PDE4 inhibitor treat-
ment may lead to greater anti-inflammatory efficacy [53].
Although our studies demonstrate that the effects of apre-
milast on TNFα secretion are mediated by both PKA and
Epac1/2 activation (Fig. 6b) it is likely that the different in-
flammatory stimuli used in the prior and current studies
may account for this apparent discrepancy, LPS stimula-
tion (present work) vs no stimulus ([53]).
These studies were carried out using a murine model
of synovial inflammation, the air pouch model, and using
murine macrophage cell lines. Both of these model sys-
tems reflect inflammatory events as they occur in pa-
tients, although neither of them are a perfect model. In
the air pouch model inflammation is induced by the in-
jection of carrageenan into an artificially created pouch
that resembles the synovium, but the lining cells, while
likely mesothelial in origin, are not synoviocytes and the
inflammatory stimulus is not physiological. Similarly, the
Raw 264.7 cells used here are derived from murine mac-
rophages but there are likely other mutations in these
cells that have rendered them immortal and which may
exert some effect on the response to drugs or inflamma-
tory stimuli. Nonetheless, these model systems permit a
detailed study of the inflammatory milieu and support
molecular probes of inflammatory signaling that are
not possible in inflamed human synovium or primary
human cells.
Conclusions
In summary, we report here that the novel PDE4 inhibi-
tor apremilast is a potent inhibitor of inflammation via
cAMP, PKA, and Epac1/2, and that interactions with the
A2AR are likely due to compartmentalization of cAMP,
rather than total cAMP changes. In an in vivo model
that mimics the synovial cavity, apremilast exerts a po-
tent anti-inflammatory action, which was not affected by
MTX in this model. These results may help to explain
the cAMP-dependent mechanism of action of apremilast
as currently labeled for use in the treatment of psoriatic
arthritis.
Additional files
Additional file 1: Figure S1. Adenosine A2A receptor (A2AR) activation
and apremilast do not additively increase responsive element binding
protein (cAMP). Raw 264.7 cells were incubated with cumulative
concentrations of apremilast (6 nM to 1 μM), apremilast + CGS21680 1μM
15 minutes before apremilast, or cumulative concentrations of CGS21680
alone (6 nM to 1 μM), followed by treatment with lipopolysaccharide
(LPS) 1 μM for 20 minutes. Then, intracellular cAMP levels were
measured as described under “Materials and methods”. Data represent
means ± standard error of the mean of at least three independent
experiments. (TIFF 170 kb)
Additional file 2: Figure S2. Permanent transduction of shRNA for
protein kinase (PKA) dramatically decreases PKA protein expression in the
Raw 264.7 cell line, as determined by western blotting. (TIFF 268 kb)
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